Inovio Pharmaceuticals, Inc.
INO
Positions held
Your positionsINO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $112.70M | Enterprise value | $84.03M | Trailing P/E | — | Forward P/E | -2.48 |
| PEG | — | Price / book | 20.57 | Beta | 1.61 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -4.1% | ROA | -84.2% | Debt / equity | 1.83 |
| Current ratio | 1.00 | Free cash flow | -$33.86M | Analyst recommendation | none | Mean target | $3.17 |
| 52w high | $2.72 | 52w low | $0.56 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.0M | -$19.7M | $3.8M | -$45.5M | -$23.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.6M | -$21.9M | -$17.5M | -$21.2M | -$23.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.2M | $0.8M | $10.3M | — |
| Op margin | -132871.3% | -51616.9% | -16036.7% | -2607.4% | — |
| Net income | -$84.9M | -$107M | -$135M | -$280M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$86.8M | -$112M | -$133M | -$268M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
2026-10-05 · PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
2026-09-30 · PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
2026-09-24 · Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
2026-09-14 · Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
2026-09-11 · Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
2026-09-10 · Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
2026-09-10 · Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
2026-09-01 · INOVIO to Participate in Upcoming Investor Conferences
2026-08-13 · --Jefferies Upgrades Inovio Pharmaceuticals to Buy From Hold, Adjusts PT to $3 From $1.80
2026-08-13 · Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
2026-08-13 · Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns